Cardiovascular drug development: pipeline, trials and approval odds
Cardiovascular drug development, from LDL cholesterol and lipoprotein(a) to heart failure and hypertension: active industry trials, historical approval odds, and the experimental drugs we track.
Key points
- Cardiovascular programs have had some of the lowest odds of approval: 4.8% from Phase 1 in the BIO 2011–2020 analysis, second-lowest of the 14 major disease areas, and the lowest approval rate after submission (82.5%).
- Cardiovascular programs also took longer than average, about 11.5 years from Phase 1 to approval versus 10.5 years overall, partly because outcome trials need thousands of patients followed for years.
- LDL cholesterol is a validated surrogate endpoint, which is why the FDA approved the oral PCSK9 inhibitor enlicitide (Lipfendra) in July 2026 on LDL lowering before its outcomes trial finished.
- Lipoprotein(a) is not a validated surrogate. In 2026, pelacarsen lowered it by 78% without reducing cardiovascular events, putting the remaining Lp(a) outcomes trials under intense scrutiny.
- Spectral Genomics tracks seven cardiovascular drugs, spanning LDL lowering (enlicitide, obicetrapib) and Lp(a) lowering (pelacarsen, olpasiran, lepodisiran, muvalaplin, zerlasiran).
Active industry trials
About 474 industry-sponsored Phase 1–3 trials in this area are active on ClinicalTrials.gov (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts come from condition searches; a trial listing several conditions can appear in more than one row.
| Condition | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
| High LDL cholesterol (hypercholesterolemia, dyslipidemia) | 37 | 34 | 47 |
| Elevated lipoprotein(a) | 6 | 11 | 11 |
| Atherosclerotic cardiovascular disease | 17 | 44 | 44 |
| Heart failure | 29 | 40 | 32 |
| Hypertension | 54 | 69 | 65 |
| Whole area | 129 | 177 | 168 |
Most active Phase 3 sponsors
- AstraZeneca (13 active Phase 3 trials)
- Novartis Pharmaceuticals (12 active Phase 3 trials)
- Eli Lilly and Company (9 active Phase 3 trials)
- Merck Sharp & Dohme LLC (7 active Phase 3 trials)
- Novo Nordisk A/S (6 active Phase 3 trials)
- Amgen (5 active Phase 3 trials)
- Insmed Incorporated (4 active Phase 3 trials)
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (4 active Phase 3 trials)
Historical approval odds
Share of programs at each stage that went on to FDA approval, 2011–2020.
| Disease area (as defined by the source) | From Phase 1 | From Phase 2 | From Phase 3 | From submission |
|---|---|---|---|---|
| Cardiovascular (n = 651) | 4.8% | 9.6% | 45.6% | 82.5% |
| All indications (n = 12,728) | 7.9% | 15.1% | 52.4% | 90.6% |
Source: BIO, Informa Pharma Intelligence, QLS Advisors (2021), likelihood-of-approval table (Figure 5b). The report does not publish which conditions it assigns to each disease area, so it is not certain that every lipid-lowering program was counted as cardiovascular. These are averages for groups of programs, not predictions for any drug. See our methodology.
Tracked drugs in this area
Enlicitide (Lipfendra)
Merck & Co. (MSD) · Oral PCSK9 inhibitor (once-daily tablet)
FDA-approved July 2026 as the first oral PCSK9 inhibitor; cardiovascular outcomes trial ongoing
Approved outside the U.S.Obicetrapib (Ubeslo)
NewAmsterdam Pharma · Small molecule (oral, once daily)
Approved in the EU in 2026 for high cholesterol; no FDA approval; 9,541-patient outcomes trial ongoing
Major setbackPelacarsen
Novartis · Antisense oligonucleotide
Phase 3 outcomes trial missed its primary endpoint despite a 78% Lp(a) reduction
Not yet approvedOlpasiran
Amgen · Small interfering RNA (siRNA)
Phase 3 cardiovascular outcomes trial ongoing; Phase 2 showed near-complete Lp(a) lowering
Not yet approvedLepodisiran
Eli Lilly and Company · Small interfering RNA (siRNA)
Phase 3 outcomes trial (ACCLAIM-Lp(a)) underway; a single dose lowered Lp(a) by about 94% in Phase 2
Not yet approvedMuvalaplin
Eli Lilly and Company · Small molecule (oral, once daily)
First oral Lp(a)-lowering drug in a Phase 3 outcomes trial (MOVE-Lp(a)), now recruiting
Not yet approvedZerlasiran
Silence Therapeutics · Small interfering RNA (siRNA)
Phase 2 complete; described by Silence as Phase 3-ready; Silence agreed to be acquired by Merck KGaA
Why cardiovascular drugs are hard to develop
Heart attacks, strokes, and cardiovascular deaths are the outcomes that matter, but they take years to accumulate, even in high-risk patients. Proving that a new drug prevents them usually means a cardiovascular outcomes trial with thousands to tens of thousands of participants. That is a major reason cardiovascular programs have historically been slower and less likely to reach approval than average. It is also why the area's big decisions arrive as rare, high-stakes readouts.
Many patients already take effective drugs, such as statins, so a new treatment must add benefit on top of good existing care. See Why Do Phase 3 Clinical Trials Fail?
Two races in lipid lowering
LDL cholesterol: a validated surrogate
Decades of trials have shown that lowering LDL cholesterol reduces cardiovascular events, so the FDA accepts LDL lowering as a basis for approval. The genetics point the same way: people born with variants that disable PCSK9 have lifelong lower LDL and far less coronary disease. That made PCSK9 a classic genetically validated target.
- Enlicitide (Merck & Co.) became the first oral PCSK9 inhibitor when the FDA approved it as Lipfendra in July 2026. Its outcomes trial is still running.
- Obicetrapib (NewAmsterdam Pharma) is an oral CETP inhibitor, a class with a troubled history. Torcetrapib increased deaths in its outcomes trial. Obicetrapib was approved in the EU in 2026, and its PREVAIL outcomes trial is the key pending test.
Lipoprotein(a): genetics without (yet) proof
Lp(a) levels are largely inherited, and genetic studies strongly link higher Lp(a) to coronary disease. Unlike LDL, however, lowering Lp(a) had never been shown to prevent events, and in 2026 the first outcomes trial to report, pelacarsen's Lp(a)HORIZON, found no reduction despite a 78% drop in Lp(a).
That makes the remaining Lp(a) programs some of the most closely watched trials in medicine:
| Drug | Developer | Approach | Status |
|---|---|---|---|
| Olpasiran | Amgen | siRNA injection | Phase 3 outcomes trial; estimated primary completion March 2028 |
| Lepodisiran | Eli Lilly | Long-acting siRNA injection | Phase 3 outcomes trial; estimated primary completion March 2029 |
| Muvalaplin | Eli Lilly | Oral small molecule | Phase 3 outcomes trial recruiting; estimated primary completion 2031 |
| Zerlasiran | Silence Therapeutics | siRNA injection | Phase 2 complete; no Phase 3 registered |
Dates are registry estimates and often change. Each drug profile logs registry changes.
Beyond lipids
The live registry table on this page shows substantial industry activity in heart failure and hypertension, two areas Spectral Genomics does not yet profile in depth. Among company programs visible in the registry are Amgen's heart-failure trial of maridebart cafraglutide and Novartis's large inclisiran outcomes trials.
Company pipelines
- Merck & Co. · NYSE: MRK
- NewAmsterdam Pharma · Nasdaq: NAMS
- Novartis · NYSE: NVS
- Amgen · Nasdaq: AMGN
- Eli Lilly and Company · NYSE: LLY
- Silence Therapeutics · Nasdaq: SLN
Sources
- Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine. 2006;354(12):1264–1272.Peer-reviewed
- Clarke R, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New England Journal of Medicine. 2009;361(26):2518–2528.Peer-reviewed
- U.S. Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol (July 17, 2026).Regulator
- American Heart Association Newsroom. Lp(a) HORIZON trial results (AHA Scientific Sessions 2026).Scientific meeting
- Barter PJ, et al. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine. 2007;357(21):2109–2122.Peer-reviewed
- BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report
- ClinicalTrials.gov: active industry trials in this areaRegistry
For education and research only. Not medical advice and not investment advice. See our disclaimer.